Safety of Saccharomyces boulardii (Florastor) in Solid Organ Transplant Patients

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Safety of Saccharomyces boulardii (Florastor) in Solid Organ Transplant Patients"

Transcription

1 Butler University Digital Butler University Undergraduate Honors Thesis Collection Undergraduate Scholarship Safety of Saccharomyces boulardii (Florastor) in Solid Organ Transplant Patients Nicole Marie Dores Butler University Follow this and additional works at: Part of the Medicinal and Pharmaceutical Chemistry Commons Recommended Citation Dores, Nicole Marie, "Safety of Saccharomyces boulardii (Florastor) in Solid Organ Transplant Patients" (2012). Undergraduate Honors Thesis Collection This Thesis is brought to you for free and open access by the Undergraduate Scholarship at Digital Butler University. It has been accepted for inclusion in Undergraduate Honors Thesis Collection by an authorized administrator of Digital Butler University. For more information, please contact

2 BUTLER UNIVERSITY HONORS PROGRAM Honors Thesis Certification Please type all information in this section: Applicant Nicole Marie Dores (Name as it is to appear on diploma) Thesis title Safety of Saccharomyces boulardii (Florastor ) in Solid Organ Transplant Patients Intended date of commencement May 12, Read, approved, and signed by: Thesis adviser(s)~4l Reader(s)..tLhUi2~ J/1/9t;~, date Date Certified by if ~.t4 -:MI L Date For Honors Program use: Level of Honors conferred: University Ma~VlIA (um LavaL Departmental 'Pnd(WlACY W(tltl I1ljhtsf HVl10CS V V)lversi tv fhm(}3 PfP (4 WI

3 Safety of Saccharomyces boulardii (Florastor ) in Solid Organ Transplant Patients A Thesis Presented to the Department of Pharmacy Practice College of Pharmacy and Health Sciences and The Honors Program of Butler University In Partial Fulfillment of the Requirements for Graduation Honors Nicole Marie Dores May 4,2012

4 Abstract Introduction: Probiotics have been promoted for use in many gastrointestinal ailments. Most studies find probiotics safe for human use, reporting no severe adverse effects. However, probiotics are live microorganisms and thus have the potential to cause infection. Transplant recipients are considered at high risk for infectious complications from probiotics due to the immunosuppressive medications used to prevent organ rejection. Nonetheless, clinicians are currently utilizing probiotics in the transplant population, due to their benefit in gastrointestinal disorders, particularly recurrent Clostridium difficile. Limited knowledge and paucity of prospective trials in this patient population demands the need for completion of studies to identify the safety of probiotics in transplant patients. Objective: The primary objective of this study was to investigate the safety of utilizing Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in kidney, pancreas, and liver transplant recipients. A secondary obj ective of this study was to evaluate the efficacy of the use of Saccharomyces boulardii to prevent antibiotic-associated diarrhea. Methods: A prospective chart review was performed to assess the safety of Saccharomyces boulardii in transplant patients. All kidney, pancreas, and liver transplant patients who received Saccharomyces boulardii were included in the safety analysis. Only those who meet criteria for the prevention of antibiotic-associated diarrhea with Saccharomyces boulardii were included in the efficacy analysis. 1

5 Results: No infections due to the probiotic, Saccharomyces boulardii, in 16 solid organ transplant patients treated were observed. Conclusion: There are multiple of case reports regarding infectious complications of probiotics, particularly in groups at high risk for infection. However, some studies have shown probiotics given immediately after transplantation may help restore normal gut flora and prevent the translocation of bacteria across the gut wall thereby preventing infections in these immunosuppressed patients. This study found no infectious complications of probiotics in solid organ transplant recipients. 2

6 Introduction: The World Health Organization and the Food and Agriculture Organization of the United Nations define probiotics as "live microorganisms which when administered in adequate amounts confer a heath benefit to the host."1 In recent years, probiotics have been promoted for use in many disease states. In the hospital setting, probiotics are mainly used to replenish the colon microflora in patients with diarrhea due to antibiotics or to prevent recurrence of disease following treatment of Clostridium difficile colitis. 2 Most studies have found probiotics safe for human use, reporting no severe adverse effects. However, probiotics are live microorganisms and have the potential to cause infection. Patients at a higher risk of developing infection from probiotic therapy include those with immunosuppressed states, critical or terminal illness, prosthetic heart valves, bowel surgery, history of rheumatic heart disease or infective endocarditis, or use of proton pump inhibitors or histamine H2 antagonists. These higher risk patients are often excluded from probiotic studies limiting knowledge concerning the safety of probiotic therapy in these populations.y'r' Organ transplant recipients are considered a high risk group for infectious complications from probiotic therapy due to the administration of immunosuppressive medications used to prevent organ rejection." Conversely, some studies have shown probiotics beneficial in restoring normal gut flora and preventing the translocation of bacteria across the gut wall and thereby preventing infections in these immunosuppressed patients. 7,8 There are no previous prospective trials regarding the use of a Saccharomyces probiotic in the solid organ transplant population. The primary objective of this study was to investigate the safety of using Saccharomyces boulardii for the prevention of antibiotic- 3

7 associated diarrhea in solid organ transplant recipients. A secondary objective of this study was to evaluate the efficacy of the use of Saccharomyces boulardii to prevent antibioticassociated diarrhea. Methods All patients> 18 years of age who were recipients of a simultaneous kidney/pancreas, pancreas after kidney, isolated pancreas or liver transplant and were initiated on Saccharomyces boulardii therapy while admitted to the organ transplant unit at Indiana University Hospital from July 1,2011 to March 1,2012 were eligible for this prospective study. Patients who were pregnant, had a known hypersensitivity to Saccharomyces spp., or received other probiotics prior to admission were excluded. Following approval from the Indiana University School of Medicine Institutional Review Board, data was collected from the electronic medical record including age, sex, admission diagnosis, medical history, concomitant information, illness, documented infection via culture results, probiotic administration and results of tests for Clostridium difficile. Clinical outcomes data was also collected which included incidence of diarrhea or constipation, infectious complications, and other serious adverse effects associated with the probiotic therapy. Data was assessed using descriptive statistics. All patients were included in the safety analysis to determine the incidence of infectious complications due to Saccharomyces boulardii. Those patients who received antibiotic therapy as well as Saccharomyces boulardii and no other probiotic were included in the efficacy analysis to determine the benefit of Saccharomyces boulardii for the prevention of antibiotic associated diarrhea. 4

8 Results: Sixteen patients received probiotics with no documented infections or other serious complications. The demographics of the patient population are shown in Table 1. Five of these patients met the criteria for efficacy analysis of prevention of antibiotic-associated diarrhea with Saccharomyces boulardii. Three of these patients experienced diarrhea. Two had been admitted with diarrhea and found to have Clostridiums difficile colitis and were treated with either the standard of care for Clostridium difficile colitis (metronidazole or vancomycin) in addition to the Saccharomyces boulardii. Both patients had resolution of their diarrhea with this treatment. The other patient experienced diarrhea after 5 days of probiotic therapy. The probiotic was continued and due to improvement of diarrhea the patient was discharged on the probiotic. Discussion: In this study, Saccharomyces boulardii therapy was well tolerated in pancreas, kidney, and liver transplant patients with no serious adverse effects. Although this was a small study, it contradicts literature showing infectious complications of probiotics particularly in patients who are immunosuppressed. Current guidelines for the prevention and treatment of Clostridium difficile infection from the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America state "administration of currently available probiotics is not recommended to prevent primary Clostridium difficile infection, as there are limited data to support this approach and there is a potential risk of bloodstream infection.,,9 These guidelines also discourage the use of Saccharomyces spp. therapy; "administration of Saccharomyces boulardii has, however, been associated with fungemia in 5

9 immunocompromised patients and in patients with central venous lines, and should be avoided in critically ill patients.?" These recommendations are based on case reports that describe infectious complications of probiotics in groups at risk for infection. In a review of 92 cases of invasive infections due to Saccharomyces spp., Saccharomyces boulardii was responsible for 37 fungemias.i" Of these patients, 32 had taken a probiotic that contained Saccharomyces boulardii. Those who had a Saccharomyces boulardii infection were more likely to have a digestive tract disease, a central venous catheter, and be hospitalized in an intensive care unit. 10 Munoz, and colleagues, II investigated an outbreak of Saccharomyces cerevisiae fungemias in an intensive care unit. The investigators revealed the commonality between the three patients with fungemia was treatment with a Saccharomyces boulardii probiotic, brand name Ultralevura. Both the probiotic strain of yeast and the blood cultures isolated from the three patients were identified by the hospital microbiology laboratory as Saccharomyces cerevisiae with identical DNA fingerprinting. Discontinuation of the probiotic product ended further infections in the unit. II Like critically ill patients, organ transplant recipients are considered high risk for infectious complications of probiotics. The purported reason suggested for this increased risk of infectious complications in transplant recipients is the immune compromised state induced from the transplant medications required to prevent rejection of the transplanted organ." Luong and colleagues 12 report their experience in which a 56-year-old male with human immunodeficiency virus underwent a double-lung transplant and developed an empyema which cultured positive for Lactobacillus rhamnosus GG, the strain of bacteria 6

10 identical to the probiotic administered as part of the standard post-transplant Clostridium difficile prophylaxis regime. 12 Riquelme and colleagues'< report a case ofa 42-year-old woman, having received a kidney-pancreas transplant developed Saccharomyces cerevisiae fungemia after treatment with Saccharomyces boulardii for Clostridium difficile. Though the strain of Saccharomyces spp. was S. cerevisiae and not S. boulardii, the investigators concluded the fungemia was a result of the administration of the probiotic as it is very difficult for most laboratories to distinguish Saccharomyces boulardii from Saccharomyces., 13 cerevtsiae. In our study, conclusions regarding efficacy cannot be made due to the limited number of patients meeting the inclusion criteria at this time. Trials have shown benefit with the use of probiotics for diarrhea. In a study conducted by Hickson and colleagues.!" 135 older adults taking antibiotics were randomized to receive either a probiotic drink containing Lactobacillus casei, Lactobacillus bulgaricus, and Streptococcus thermophilus or a sterile milkshake. The incidence of both antibiotic-associated and Clostridium difficile diarrhea was decreased in the probiotic group. In a review of probiotics by Imhoff and Karpa, 15 a tendency towards benefits from probiotics was observed. Clinical trials of probiotics containing multiple strains were shown to be most favorable for primary prevention of Clostridium difjicile associated disease. However, clinical trials and case reports of the probiotic Saccharomyces boulardii in combination with high-dose vancomycin were most advantageous for the prevention of recurrence di 2,15 isease. Current guidelines for the use of nutritional support in critical ill patients from the Society of Critical Care Medicine and the American Society for Parenteral and Enteral 7

11 Nutrition state, "administration of probiotic agents has been shown to improve outcome (most consistently by decreasing infection) in specific critically ill patient populations involving transplantation, major abdominal surgery, and severe trauma.v'" However, the guidelines do not recommend one probiotic strain or combination over another. "It seems that each species may have different effects and variable impact on patient outcome, making it difficult to make broad categorical recommendations." 16 Rayes and colleagues 7,8 have shown the administration of probiotics immediately after transplantation may help restore normal gut flora and prevent translocation of bacteria across the gut wall thus preventing infections in these immunosuppressed patients. In a group of 66 adult liver transplant patients, those patients treated with a probiotic containing Pediacoccus pentosaceus, Leuconostoc mesenteroides, Lactobacillus paracasei, and Lactobacillus plantarum twice daily for 14 days immediately post-transplantation showed a significant decrease in post-operative infections. Post-operative infections were seen in 48% of patients who did not receive probiotic therapy and 3% of patients who received probiotic therapy.' Conclusion: Although the use ofprobiotics in solid organ transplant recipients and other immunocompromised individuals is controversial, they are still utilized in these populations. This prospective trial found no infectious complications with the administration of the probiotic Saccharomyces boulardii in sixteen solid organ transplant patients. Further research is required to determine the safety of probiotics, including Saccharomyces boulardii, in the solid organ transplant population. 8

12 References: 1. FAO/WHO. Guidelines for the evaluation ofprobiotics in food. Food and Agriculture Organization of the United Nations Web site: ftp://ftp.fao.org/es/esn/food/wgreport2.pdf. Published Accessed June 24, McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA.1994;271(24): Wallace B. Clinical use ofprobiotics in the pediatric population. Nutr Clin Pract. 2009;24(1): Rohde CL, Bartolini V, Jones N. The use ofprobiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium d~fficile-associated diarrhea. Nutr Clin Pract. 2009;24(1): Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol. 2005;54: Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6): Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant. 2005;5(1): Rayes N, Seehofer D, Hansen S, et al. Early enteral supply of Lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation. 2002;74(1):

13 9. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for health care epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Ho,sp Epidemiol. 2010;31(5): Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis. 2005;41(11): Munoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40(11): Luong ML, Sareyyupoglu B, Nguyen MH, et al. Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection? Transpl Infect Dis. 2010;12(6): Riquelme A, Calvo MA, Guzman AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003;36(1): Hickson M, D'Souza AL, Muthu Net al. Use of pro biotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomized double blind placebo controlled trial. BMJ. 2007;335(7610): Imhoff A, Karpa K. Is there a future for probiotics in preventing Clostridium difficileassociated disease and treatment of recurrent episodes? Nutr Clin Pract. 2009;24(1):

14 16. Martindale RG, McClave SA, Vanek VW, et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition: Executive Summary. Crit Care Med. 2009;37(5):

The use of probiotics to prevent antibiotic induced diarrhoea. Dr Mary Hickson Research Dietitian Imperial College Healthcare NHS Trust

The use of probiotics to prevent antibiotic induced diarrhoea. Dr Mary Hickson Research Dietitian Imperial College Healthcare NHS Trust The use of probiotics to prevent antibiotic induced diarrhoea. Dr Mary Hickson Research Dietitian Imperial College Healthcare NHS Trust Bacteria Nomenclature Division e.g. Firmicutes Class e.g. Bacilli

More information

Updates to pharmacological management in the prevention of recurrent Clostridium difficile

Updates to pharmacological management in the prevention of recurrent Clostridium difficile Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing

More information

Long-Term Care Updates

Long-Term Care Updates Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause

More information

11/2/2016. Objectives. Definition of probiotics. What is and what is not a probiotic? What is and what is not a probiotic?

11/2/2016. Objectives. Definition of probiotics. What is and what is not a probiotic? What is and what is not a probiotic? A Consumer s Guide to Probiotics and Health Wellness Wednesday November 2, 2016 Wendy Dahl RD PhD FDC Associate Professor, Food Science and Human Nutrition, UF/IFAS Objectives To outline current evidence

More information

Update on Clostridium difficile infection.

Update on Clostridium difficile infection. Update on Clostridium difficile infection. K. Honein Gastroenterologist, HDF Associate Professor Head of Medicine Department St Joseph University-Beirut. Introduction Gram+anaerobic bacillus responsible

More information

PROBIOTICS. The Ultimate Flora Difference

PROBIOTICS. The Ultimate Flora Difference In the Refrigerator Section! PROBIOTICS High-Potency Daily, Critical Care and Targeted Probiotic Formulas to Improve Regularity, Strengthen Natural Defenses and Promote Overall Digestion * The ReNew Life

More information

The effect of probiotics on animal health: a focus on host s natural intestinal defenses

The effect of probiotics on animal health: a focus on host s natural intestinal defenses The effect of probiotics on animal health: a focus on host s natural intestinal defenses Guillaume Tabouret Animal Health Dept. Joint Unit 1225 Host Pathogens Interactions History of probiotics and definition

More information

Probiotics. Wide spectrum of important health benefits

Probiotics. Wide spectrum of important health benefits Probiotics Part 1: What Are Probiotics? Probiotics are live microorganisms that inhabit the respiratory and gastrointestinal tracts and the skin. They are often referred to as friendly bacteria as they

More information

Probiotics and Prebiotics: Medicine or Myth. Objectives 5/31/2013. Speaker s Disclosure Statement & Non Commercialism Agreement

Probiotics and Prebiotics: Medicine or Myth. Objectives 5/31/2013. Speaker s Disclosure Statement & Non Commercialism Agreement Probiotics and Prebiotics: Medicine or Myth Gregory Matsuura, Pharm.D., BCPS (AQ ID) Objectives Recall the differences between prebiotics and probiotics and their uses Identify the specific agents used

More information

Rapid Recovery Hyperbarics 9439 Archibald Ave. Suite 104 Rancho Cucamonga CA,

Rapid Recovery Hyperbarics 9439 Archibald Ave. Suite 104 Rancho Cucamonga CA, Clinical Gastroenterology and Hepatology Gastroenterologist's Guide to Probiotics Matthew a. Ciorba, MD Posted: 09/13/2012; Clin Gastroenterol Hepatol. 2012;10(9):960-968. 2012 G Institute bstract and

More information

Prevention and Therapy of Antibiotic Associated Diarrhea (ADD) through Probiotics

Prevention and Therapy of Antibiotic Associated Diarrhea (ADD) through Probiotics Prevention and Therapy of Antibiotic Associated Diarrhea (ADD) through Probiotics DGMIM, 15.-16.10.2010 16.10.2010 Stuttgart Prof. Rémy Meier, MD GI-Department University Hospital Liestal, Switzerland

More information

Probiotics. NOW Guide to Probiotics

Probiotics. NOW Guide to Probiotics Probiotics NOW Guide to Probiotics The Health Benefits of Probiotics Microorganisms for Health Did you know that you have trillions of microorganisms, including bacteria and yeast, living in and on your

More information

Clostridium difficile Infection (CDI) Management Guideline

Clostridium difficile Infection (CDI) Management Guideline Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for

More information

Predictors of Mortality and Morbidity in Clostridium Difficile Infection

Predictors of Mortality and Morbidity in Clostridium Difficile Infection Predictors of Mortality and Morbidity in Clostridium Difficile Infection Jill Dixon, Brian F. Menezes Corresponding author: dippers82@hotmail.com Pages 23-26 ISSN 1840-4529 http://www.iomcworld.com/ijcrimph

More information

Clinical Report: Probiotics and Prebiotics in Pediatrics

Clinical Report: Probiotics and Prebiotics in Pediatrics www.medscape.com Authors and Disclosures Author(s) Dan W. Thomas, MD Professor of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California; Head, Division of Gastroenterology

More information

Fecal Microbiota Transplant Current Role and Potential Future

Fecal Microbiota Transplant Current Role and Potential Future Fecal Microbiota Transplant Current Role and Potential Future Stephen R. Freeman, M.D. Associate Professor of Medicine University of Colorado Denver Anschutz Medical Campus Division of Gastroenterology

More information

Probiotiques et infections, Un sujet «incertain»

Probiotiques et infections, Un sujet «incertain» Probiotiques et infections, Un sujet «incertain» antoine.andremont@bch.aphp.fr 1 2 General : So, a strict roadmad. Definition, Market Recent findings in : Infectious diarrhea, C. dif, VRE, UTI, VAP, Pediatrics,

More information

NEERJA HAJELA, PhD Head Science Yakult Danone India Pvt. Ltd.

NEERJA HAJELA, PhD Head Science Yakult Danone India Pvt. Ltd. NEERJA HAJELA, PhD Head Science Yakult Danone India Pvt. Ltd. What we already know. Functional Foods - foods that provide a health benefit beyond the traditional nutrients it contains.. American Dietetics

More information

TOP 10 LEAKY GUT SUPPLEMENTS

TOP 10 LEAKY GUT SUPPLEMENTS TOP 10 LEAKY GUT SUPPLEMENTS HEALING LEAKY GUT Leaky Gut Supplements Leaky gut syndrome is a condition where undigested proteins like gluten, toxins and microbes can pass into the bloodstream. Another

More information

more intense treatments are needed to get rid of the infection.

more intense treatments are needed to get rid of the infection. What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting

More information

Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study

Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized Patients: A Single Center Study ORIGINAL ARTICLE ISSN 1598-9100(Print) ISSN 2288-1956(Online) http://dx.doi.org/10.5217/ir.2014.12.4.299 Intest Res 2014;12(4):299-305 Long-Term Clinical Outcome of Clostridium difficile Infection in Hospitalized

More information

6.2 Enteral Nutrition (Other): Probiotics March 2013

6.2 Enteral Nutrition (Other): Probiotics March 2013 6.2 Enteral Nutrition (Other): Probiotics March 2013 2013 Recommendation: Based on 3 level 1 and 20 level 2 studies, the use of probiotics should be considered in critically ill patients. 2013 Discussion:

More information

Consequences of Clostridium difficile infection: understanding the healthcare burden

Consequences of Clostridium difficile infection: understanding the healthcare burden REVIEW 10.1111/1469-0691.12064 Consequences of Clostridium difficile infection: understanding the healthcare burden E. Bouza 1,2 1) Department of Microbiology and Infectious Diseases, Hospital General

More information

Treating and Preventing. C. difficile Infections A Review of the Research for Adults

Treating and Preventing. C. difficile Infections A Review of the Research for Adults Treating and Preventing C. difficile Infections A Review of the Research for Adults e Is This Information Right for Me? This information is right for you if: Your health care professional has said that

More information

When can infants and children benefit from probiotics?

When can infants and children benefit from probiotics? When can infants and children benefit from probiotics? The latest studies indicate that probiotics can help with colic, eczema, and certain types of diarrhea. They may also help with upper respiratory

More information

Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebocontrolled

Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebocontrolled Journal of Hospital Infection xxx (2013) 1e7 Available online at www.sciencedirect.com Journal of Hospital Infection journal homepage: www.elsevierhealth.com/journals/jhin Probiotic VSL#3 prevents antibiotic-associated

More information

Labeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)

Labeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD) Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum

More information

Sunday, May 1, 16.

Sunday, May 1, 16. http://6abc.com/health/healthcheck-foodsthat-may-improve-your-digestion/547915/ The world of probiotics rajiv K sharma md Dr. RAJIV SHARMA is a Board Certified Physician. He is a practicing Gastroenterologist

More information

Probiotics. Beyond Digestion & Immunity NEWS YOU CAN USE

Probiotics. Beyond Digestion & Immunity NEWS YOU CAN USE Beyond Digestion & Immunity Health Benefits of Probiotics Probiotic cultures, once known only for their role in making fermented foods, have perked the interest of scientists. New studies are uncovering

More information

An Emerging Trend of High Dose Probiotic Use in Clinical Practice -A Brief Survey-

An Emerging Trend of High Dose Probiotic Use in Clinical Practice -A Brief Survey- -Technical Report- An Emerging Trend of High Dose Use in Clinical Practice -A Brief Survey- October 2011 The Point Institute of Nutraceutical Research is focused on examining and disseminating information

More information

Properties of Evidence-Based Probiotics for Human Health

Properties of Evidence-Based Probiotics for Human Health DK3341_book.fm Page 109 Wednesday, July 27, 2005 8:26 AM 5 Properties of Evidence-Based Probiotics for Human Health Lynne V. McFarland and Gary W. Elmer CONTENTS 5.1 Introduction... 110 5.2 Desirable Properties

More information

Clostridium difficile, a spore forming

Clostridium difficile, a spore forming Infectious Diseases Probiotics for Clostridium difficile Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii Marisel Segarra-Newnham Author information provided at the

More information

HMF Probiotics PROFESSIONAL PRODUCT GUIDE

HMF Probiotics PROFESSIONAL PRODUCT GUIDE HMF Probiotics PROFESSIONAL PRODUCT GUIDE NEW New products inside Research-driven, proprietary, human-sourced strains Visit www.seroyal.com/genestrabrands to view the entire GENESTRA BRANDS line Dedicated

More information

The incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment.

The incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment. C. DIFFICILE Case definition CONFIRMED CASE A patient is defined as a case if they are one year of age or older AND have one of the following requirements: A laboratory confirmation of a positive toxin

More information

DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News. Volume 3, Number 6, June 2015

DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News. Volume 3, Number 6, June 2015 DUKE ANTIMICROBIAL STEWARDSHIP OUTREACH NETWORK (DASON) Antimicrobial Stewardship News Volume 3, Number 6, June 2015 Diagnostic Testing for Clostridium difficile Infection Background Clostridium difficile

More information

continuing education for pharmacists Volume XXXIV, No. 8

continuing education for pharmacists Volume XXXIV, No. 8 continuing education for pharmacists Volume XXXIV, No. 8 Prebiotics, Probiotics, and Synbiotics: Their Therapeutic Role Cortney M. Mospan, PharmD, BCACP, CGP, Assistant Professor of Pharmacy, Wingate University

More information

Lactobacillus GG in the prevention of antibioticassociated

Lactobacillus GG in the prevention of antibioticassociated Lactobacillus GG in the prevention of antibioticassociated diarrhea in children Jon A. Vanderhoof, MD, David B. Whitney, MD, Dean L. Antonson, MD, Terri L. Hanner, RN, James V. Lupo, PhD, and Rosemary

More information

Clinical Policy Bulletin: Fecal Bacteriotherapy

Clinical Policy Bulletin: Fecal Bacteriotherapy Clinical Policy Bulletin: Fecal Bacteriotherapy Number: 0844 Policy Aetna considers fecal bacteriotherapy medically necessary for persons with Clostridium difficile infection, with infection confirmed

More information

C. Difficile: Prevention, Treatment and Role of Fecal Transplant. Clostridium Difficile Infection (CDI) Learning Objectives

C. Difficile: Prevention, Treatment and Role of Fecal Transplant. Clostridium Difficile Infection (CDI) Learning Objectives C. Difficile: Prevention, Treatment and Role of Fecal Transplant Learning Objectives Recognize and mitigate risk factors for C. difficile infection Apply recent data on treatment of C. difficile infection

More information

New approaches to treating Clostridium difficile Infection

New approaches to treating Clostridium difficile Infection 7:45 8:45 am New Approaches to Treating C. difficile Infection SPEAKER Fred A. Lopez, MD, MACP Presenter Disclosure Information The following relationships exist related to this presentation: Fred A. Lopez,

More information

Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU

Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance

More information

OBESITY CAN IT BE REDUCED BY IMPROVING THE MICROBIOTA? MIROSŁAWA GAŁĘCKA, MD, PHD INSTITUTE OF MICROECOLOGY, POLAND

OBESITY CAN IT BE REDUCED BY IMPROVING THE MICROBIOTA? MIROSŁAWA GAŁĘCKA, MD, PHD INSTITUTE OF MICROECOLOGY, POLAND OBESITY CAN IT BE REDUCED BY IMPROVING THE MICROBIOTA? MIROSŁAWA GAŁĘCKA, MD, PHD INSTITUTE OF MICROECOLOGY, POLAND Gut microbiota play an important role in the regulation of energy balance and weight

More information

E. coli Nissle 1917 A Unique Medical Probiotic and it s Clinical Applications. Sudesh Samuel Scientific Director Amber Laboratories

E. coli Nissle 1917 A Unique Medical Probiotic and it s Clinical Applications. Sudesh Samuel Scientific Director Amber Laboratories E. coli Nissle 1917 A Unique Medical Probiotic and it s Clinical Applications Sudesh Samuel Scientific Director Amber Laboratories Content E. coli s background Gut Microbiome Pathogenic E. coli Probiotic

More information

Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection

Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection GASTROENTEROLOGY 2009;136:1206 1214 Prospective Derivation and Validation of a Clinical Prediction Rule for Recurrent Clostridium difficile Infection MARY Y. HU,* KIANOOSH KATCHAR,* LORRAINE KYNE, SEEMA

More information

The role of gut microbiome in IBS

The role of gut microbiome in IBS The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard

More information

Factors associated with prolonged symptoms and severe disease due to Clostridium difficile

Factors associated with prolonged symptoms and severe disease due to Clostridium difficile Age and Ageing 1999; 28: 107 113 Factors associated with prolonged symptoms and severe disease due to Clostridium difficile LORRAINE KYNE, CONCEPTA MERRY 2,BRIAN O CONNELL 2,ALAN KELLY 3,CONOR KEANE 2,

More information

Kevin Whelan and Clio E Myers

Kevin Whelan and Clio E Myers Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials 1 3 Kevin Whelan and Clio E Myers ABSTRACT Background:

More information

PROBIOTICS: HEALTHY BACTERIA USED IN HEART SURGERY PATIENTS. Crista Lynn Lickteig. A Thesis Submitted to the Faculty of the

PROBIOTICS: HEALTHY BACTERIA USED IN HEART SURGERY PATIENTS. Crista Lynn Lickteig. A Thesis Submitted to the Faculty of the 1 PROBIOTICS: HEALTHY BACTERIA USED IN HEART SURGERY PATIENTS By Crista Lynn Lickteig A Thesis Submitted to the Faculty of the DEPARTMENT OF MEDICAL PHARMACOLOGY In Partial Fulfillment of the Requirements

More information

ADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA

ADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA ADJUVANT TIGECYCLINE FOR SEVERE CLOSTRIDIUM DIFFICILE-ASSOCIATED DIARRHEA Candace Marr, DO Catholic Health System University at Buffalo, NY Kevin Shiley, MD Catholic Health System Buffalo, NY FINANCIAL

More information

REF/2014/10/ CTRI Website URL -

REF/2014/10/ CTRI Website URL - Clinical Trial Details (PDF Generation Date :- Sat, 16 Dec 2017 12:41:27 GMT) CTRI Number Last Modified On 16/04/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study

More information

Antibiotic use, gastroenteritis and respiratory illness in South Australian children

Antibiotic use, gastroenteritis and respiratory illness in South Australian children Epidemiol. Infect. (2002), 129, 507 513. f 2002 Cambridge University Press DOI: 10.1017/S0950268802007628 Printed in the United Kingdom Antibiotic use, gastroenteritis and respiratory illness in South

More information

Form 105 is completed and key entered for each participant who consents to the study.

Form 105 is completed and key entered for each participant who consents to the study. Revision 04/28/2016 Form #105 Page 1 of 5 Pilot Clinical Trials in CKD Screening Form #105 TarGut Microbiome Form 105 is completed and key entered for each participant who consents to the study. 1. Identification

More information

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES

DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health

More information

EED INTERVENTIONS: PRE- AND PRO-BIOTIC SAFETY

EED INTERVENTIONS: PRE- AND PRO-BIOTIC SAFETY EED INTERVENTIONS: PRE- AND PRO-BIOTIC SAFETY Produced by: Dietrich, C.; Kidane, L.; Babigumira, J. Agenda Agenda Timeline Project Background and Objectives Key Takeaways Approach & Rationale Methods Results

More information

INDIVIDUAL STUDY SYNOPSIS LINPT01. EudraCT No

INDIVIDUAL STUDY SYNOPSIS LINPT01. EudraCT No NAME OF SPONSOR: Lek Pharmaceuticals d.d. Verovškov 57 SI-1526 Ljubljana NAME OF FINISHED PRODUCT: Linef Forte, trde kapsule INDIVIDUAL STUDY SYNOPSIS LINPT01 EudraCT No.2009-010713-69 NAME OF ACTIVE INGREDIENTS:

More information

Probiotic use in preventing postoperative infection in liver transplant patients

Probiotic use in preventing postoperative infection in liver transplant patients Original Article Probiotic use in preventing postoperative infection in liver transplant patients Yan Zhang 1, Jim Chen 1, Jinshan Wu 1, Helen Chalson 2, Lynn Merigan 2, Andrew Mitchell 1 1 Sir Charles

More information

Gut Microbes: Potential targets in the prevention and treatment of IBD. Neelendu Dey, MD Instructor Division of Gastroenterology

Gut Microbes: Potential targets in the prevention and treatment of IBD. Neelendu Dey, MD Instructor Division of Gastroenterology Gut Microbes: Potential targets in the prevention and treatment of IBD Neelendu Dey, MD Instructor Division of Gastroenterology Disclosure The following are my disclosures. Potential conflicts of interest

More information

Featured Topic: Peppermint for Digestive Problems (4 slides)

Featured Topic: Peppermint for Digestive Problems (4 slides) Featured Topic: Peppermint for Digestive Problems (4 slides) The Power of Peppermint Peppermint relieves gas reduces inflammation in the digestive tract stops the colonization of harmful bacteria in the

More information

Fungal Infections in Patients with Severe Acute Pancreatitis and the Use of Prophylactic Therapy

Fungal Infections in Patients with Severe Acute Pancreatitis and the Use of Prophylactic Therapy MAJOR ARTICLE Fungal Infections in Patients with Severe Acute Pancreatitis and the Use of Prophylactic Therapy Jan J. De Waele, 1 D. Vogelaers, 2 S. Blot, 1 and F. Colardyn 1 1 Intensive Care Unit and

More information

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 5

COMPLETE DIGESTIVE STOOL ANALYSIS - Level 5 COMPLETE DIGESTIVE STOOL ANALYSIS - Level 5 MACROSCOPIC DESCRIPTION Stool Colour Brown Result Range Brown Markers Colour - Brown is the colour of normal stool. Other colours may indicate abnormal GIT conditions.

More information

Clostridium difficile associated diarrhea (CDAD) has emerged. Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease

Clostridium difficile associated diarrhea (CDAD) has emerged. Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:339 344 Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease JOSEPH F. RODEMANN,* ERIK R. DUBBERKE, KIMBERLY A. RESKE, DA HEA SEO,*

More information

MULTI-SPECIES DIRECT FED MICROBIAL SUPPLEMENT. Product Catalog June Cedar Falls Road Menomonie, WI

MULTI-SPECIES DIRECT FED MICROBIAL SUPPLEMENT. Product Catalog June Cedar Falls Road Menomonie, WI MULTI-SPECIES DIRECT FED MICROBIAL SUPPLEMENT Product Catalog June 2014 302 Cedar Falls Road Menomonie, WI 54751 www.probios.com 715.231.1234 the world leader in DFMs (direct-fed microbials) Probios microbial

More information

Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis

Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis Manzanares et al. Critical Care (2016) 20:262 DOI 10.1186/s13054-016-1434-y RESEARCH Open Access Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis William Manzanares

More information

Spectrum of Diverticular Disease. Outline

Spectrum of Diverticular Disease. Outline Spectrum of Disease ACG Postgraduate Course January 24, 2015 Lisa Strate, MD, MPH Associate Professor of Medicine University of Washington, Seattle, WA Outline Traditional theories and updated perspectives

More information

TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS

TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult

More information

CLOSTRIDIUM DIFFICILE INFECTION (CDI): THE HIDDEN BURDEN

CLOSTRIDIUM DIFFICILE INFECTION (CDI): THE HIDDEN BURDEN CLOSTRIDIUM DIFFICILE INFECTION (CDI): THE HIDDEN BURDEN Introduction to Clostridium difficile C. difficile is a Gram-positive, spore-forming, anaerobic bacillus that was first identified in 1935 1 C.

More information

What do Cochrane systematic reviews say about probiotics as preventive interventions?

What do Cochrane systematic reviews say about probiotics as preventive interventions? COCHRANE HIGHLIGHT DOI: 10.1590/1516-3180.2017.0310241017 What do Cochrane systematic reviews say about probiotics as preventive interventions? Vinícius Lopes Braga I, Luana Pompeu dos Santos Rocha II,

More information

Beta Glucan Synbiotic Formula Brief

Beta Glucan Synbiotic Formula Brief Beta Glucan Synbiotic Formula Brief The Philosophy Complex chronic diseases are a mounting problem worldwide with many factors giving rise to a pandemic concern. Pollution, life style choices, stress levels,

More information

Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review

Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated

More information

Hospital-acquired diarrhoea in elderly patients: epidemiology and staff awareness

Hospital-acquired diarrhoea in elderly patients: epidemiology and staff awareness Age and Ageing 1998; 27: 339-343 Hospital-acquired diarrhoea in elderly patients: epidemiology and staff awareness LORRAINE KYNE, AIDEEN MORAN, CONOR KEANE 1, DESMOND O'NEILL Age-Related Health Cane, Meath

More information

Clostridium difficile infection in an endemic setting in the Netherlands

Clostridium difficile infection in an endemic setting in the Netherlands Eur J Clin Microbiol Infect Dis (2011) 30:587 593 DOI 10.1007/s10096-010-1127-4 ARTICLE Clostridium difficile infection in an endemic setting in the Netherlands M. P. M. Hensgens & A. Goorhuis & C. M.

More information

What reute do we take with Lactobacillus reuteri for antibiotic associated diarrhea? Iona Berger August 16, 2016

What reute do we take with Lactobacillus reuteri for antibiotic associated diarrhea? Iona Berger August 16, 2016 What reute do we take with Lactobacillus reuteri for antibiotic associated diarrhea? Iona Berger August 16, 2016 1 Objectives o Describe the evidence for probiotics (e.g. lactobacillus reuteri) for treatment

More information

Evaluating the CT Diagnosis of Clostridium difficile Colitis: Should CT Guide Therapy?

Evaluating the CT Diagnosis of Clostridium difficile Colitis: Should CT Guide Therapy? Iain D. C. Kirkpatrick 1 Howard M. Greenberg Received April 7, 2000; accepted after revision August 24, 2000. 1 Both authors: Department of Radiology, University of Manitoba, Health Sciences Centre, 820

More information

The Effects of Omega-3 Fatty Acids on Saccharomyces Cerevisiae Inositol Pathway Mutants

The Effects of Omega-3 Fatty Acids on Saccharomyces Cerevisiae Inositol Pathway Mutants Andrews University Digital Commons @ Andrews University Honors Theses Undergraduate Research 2011 The Effects of Omega-3 Fatty Acids on Saccharomyces Cerevisiae Inositol Pathway Mutants Daniel Antonio

More information

Seppo Salminen Mimi Tang

Seppo Salminen Mimi Tang Koletzko B. (ed): Pediatric Nutrition in Practice. Basel, Karger, 2008, pp 80 84 1 General Aspects of Childhood Nutrition 1.8 Gut Microbiota in Infants Seppo Salminen Mimi Tang Key Words M i c r o b i

More information

Effect of fructooligosaccharide fortification on quality characteristic of some fruit juice beverages (apple &orange juice)

Effect of fructooligosaccharide fortification on quality characteristic of some fruit juice beverages (apple &orange juice) International Journal of Farming and Allied Sciences Available online at www.ijfas.com 2014 IJFAS Journal-2014-3-2/141-146/ 28 February, 2014 ISSN 2322-4134 2014 IJFAS Effect of fructooligosaccharide fortification

More information

FIS 2013, Birmingham

FIS 2013, Birmingham Fidaxomicin: CDDFT Case Studies Dr Deepa Nayar County Durham and Darlington Foundation Trust FIS 2013, Birmingham This meeting has been initiated and funded by Astellas Pharma Ltd. County Durham and Darlington

More information

Anti diarrheal medication for the treatment of diarrhea induced by the Ebola virus

Anti diarrheal medication for the treatment of diarrhea induced by the Ebola virus Anti diarrheal medication for the treatment of diarrhea induced by the Ebola virus The supportive care regimens used during the Ebola hemorrhagic fever outbreak in Kikwit, Democratic Republic of the Congo

More information

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management Microbiome in You: Optimizing Gut Bacteria for Better IBD Management KT Park, M.D., M.S. Assistant Professor Co-Director, Stanford Children s Inflammatory Bowel Disease Center Stanford University School

More information

Probiotic Series. Product Innovation for a Healthy Microbiome* Featuring New Products including the PureBi Ome Line

Probiotic Series. Product Innovation for a Healthy Microbiome* Featuring New Products including the PureBi Ome Line Probiotic Series Product Innovation for a Healthy Microbiome* Featuring New Products including the PureBi Ome Line *These statements have not been evaluated by the Food and Drug Administration. These products

More information

PENICILLIN V POTASSIUM - penicillin v potassium tablet, film coated Aurobindo Pharma Limited

PENICILLIN V POTASSIUM - penicillin v potassium tablet, film coated Aurobindo Pharma Limited PENICILLIN V POTASSIUM - penicillin v potassium tablet, film coated To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial

More information

The Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain

The Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain The Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain Michael T. Bailey, Ph.D. Center for Microbial Pathogenesis The Research Institute, Nationwide Children s Hospital Department

More information

PROBIOTICS: BENEFICIAL BACTERIA FOR HEALTH AND LONGEVITY

PROBIOTICS: BENEFICIAL BACTERIA FOR HEALTH AND LONGEVITY PROBIOTICS: BENEFICIAL BACTERIA FOR HEALTH AND LONGEVITY by Dennis Clark, Ph.D. Table of Contents Why Read This Book? 1 Chapter 1. The Probiotic Decision: A Personal Story 2 Development of a Health Disaster

More information

Epidemiology and Laboratory Diagnosis of Fungal Diseases

Epidemiology and Laboratory Diagnosis of Fungal Diseases Medical Mycology (BIOL 4849) Summer 2007 Dr. Cooper Epidemiology of Mycoses Epidemiology and Laboratory Diagnosis of Fungal Diseases Mycosis (pl., mycoses) - an infection caused by a fungus Two broad categories

More information

Opportunistic infections of the digestive system. Bernhard Stamm Switzerland

Opportunistic infections of the digestive system. Bernhard Stamm Switzerland Opportunistic infections of the digestive system Bernhard Stamm Switzerland stamm.bernhard@gmail.com Infectious disease pathology... lacks a methodical approach is most of the time ambiguous time consuming...

More information

Ochieng et al. Gut Microbes 2014;5:6: ; Mahlen SD. Clin Microbiol Rev 2011;24:

Ochieng et al. Gut Microbes 2014;5:6: ; Mahlen SD. Clin Microbiol Rev 2011;24: Ochieng et al. Gut Microbes 2014;5:6:729-726; Mahlen SD. Clin Microbiol Rev 2011;24:755-91. Hertle R, et al. Infect Immun 1999;67:817-25; Hertle R and Schwarz H. BMC Infect Dis 2004;4:16 Fisher RG. Serratia.

More information

Summary of Product Characteristics

Summary of Product Characteristics Brand Name: OXALO [Pre Probiotic] Capsules Therapeutic Category: Prevention of Stone Formation Urinary tract stone disease has been a part of the human condition for millennia; in fact, bladder and kidney

More information

Vancomycin: Class: Antibiotic.

Vancomycin: Class: Antibiotic. Vancomycin: Class: Antibiotic. Indications: Treatment of patients with infections caused by staphylococcal species and streptococcal Species. Available dosage form in the hospital: 1G VIAL, 500MG VIAL.

More information

Dr. Eisenstein s Minimum Daily Probiotics Recommendations Colony Forming Units (CFU) Please click on the image

Dr. Eisenstein s Minimum Daily Probiotics Recommendations Colony Forming Units (CFU) Please click on the image Dr. Eisenstein s Minimum Daily Probiotics Recommendations Colony Forming Units (CFU) Please click on the image 1. Health maintenance adults 20 Billion CFU daily 2. Children 5 Billion CFU daily 3. Colds

More information

Impact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length of Stay in Laparoscopic Colorectal Surgeries

Impact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length of Stay in Laparoscopic Colorectal Surgeries Journal of Pharmacy and Pharmacology 4 (2016) 521-525 doi: 10.17265/2328-2150/2016.10.001 D DAVID PUBLISHING Impact of a Pharmacist Implemented Protocol on Overall Use of Alvimopan (Entereg ) and Length

More information

A comprehensive review on Probiotics

A comprehensive review on Probiotics Available online at www.ijpab.com INTERNATIONAL JOURNAL OF PURE & APPLIED BIOSCIENCE ISSN: 2320 7051 Int. J. Pure App. Biosci. 3 (2): 286-290 (2015) Review Article A comprehensive review on Probiotics

More information

Probiotics: 'Living Drugs'

Probiotics: 'Living Drugs' Probiotics: 'Living Drugs' Gary W. Elmer Am J Health-Syst Pharm 58(12):1101-1109, 2001. 2001 American Society of Health-System Pharmacists Abstract and Introduction Abstract The uses, mechanisms of action,

More information

Modulation of abdominal pain by probiotics. Anna Lyra, PhD DuPont Nutrition & Health

Modulation of abdominal pain by probiotics. Anna Lyra, PhD DuPont Nutrition & Health Modulation of abdominal pain by probiotics Anna Lyra, PhD DuPont Nutrition & Health Functional gastrointestinal (GI) wellbeing Up to 70% suffer from functional GI symptoms - ¾ do not seek medical care

More information

Why Probiotics are Good for Your Horse

Why Probiotics are Good for Your Horse Why Probiotics are Good for Your Horse A Dakota Frost When I got Dakota as a young colt, I wanted to do everything right. As I reflect upon the events that occurred, I came to realize I didn t do anything

More information

FECAL TRANSPLANTATION

FECAL TRANSPLANTATION FECAL TRANSPLANTATION From Theory to Practice in Ridge Meadows Edward Auersperg 13 January 2016 The Human Genome How many different chromosomes do humans have? 46 chromosomes 23 pairs The Human Genome

More information

Do Probiotics Provide Adequate Relief From Overall Symptoms, Including Abdominal Pain and Bloating, in Adults With Irritable Bowel Syndrome?

Do Probiotics Provide Adequate Relief From Overall Symptoms, Including Abdominal Pain and Bloating, in Adults With Irritable Bowel Syndrome? Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Do Probiotics Provide Adequate Relief

More information

GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT

GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT GASTRO-INTESTINAL TRACT INFECTIONS - ANTIMICROBIAL MANAGEMENT Name & Title Of Author: Dr Linda Jewes, Consultant Microbiologist Date Amended: December 2016 Approved by Committee/Group: Drugs & Therapeutics

More information